You have 9 free searches left this month | for more free features.

Flt3l

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)

Recruiting
  • Acute Myeloid Leukemia
  • Miami, Florida
    Miami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Graft Vs Host Disease Trial in Chapel Hill (Fluorothymidine (FLT))

Active, not recruiting
  • Graft Vs Host Disease
  • Fluorothymidine (FLT)
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Mar 21, 2022

FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)

Available
  • FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
  • (no location specified)
Oct 18, 2022

Xospata in Relapsed or Refractory Acute Myeloid Leukemia With

Recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Gilteritinib Exposure
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +4 more
Aug 18, 2022

Acute Myeloid Leukemia Trial in Spain (Quizartinib, Placebo oral tablet, Cytarabine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Santiago De Compostela, A Coruña, Spain
  • +44 more
Jan 20, 2022

Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia Trial in Columbus (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jan 4, 2022

Ewing Sarcoma Trial in United States (drug, diagnostic test, other)

Recruiting
  • Ewing Sarcoma
  • Trabectedin 1 MG [Yondelis]
  • +3 more
  • Los Angeles, California
  • +5 more
Aug 15, 2022

Advanced Cancer Trial in Houston (FLT-PET)

Completed
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 3, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial in Duarte, Palo Alto, Houston (AMG 553)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • AMG 553
  • Duarte, California
  • +2 more
Dec 22, 2021

B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

Not yet recruiting
  • B7-H3-positive Relapsed/ Refractory Neuroblastoma
  • T cell injection targeting FLT3 chimeric antigen receptor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Nov 1, 2022

Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)

Terminated
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +7 more
Mar 14, 2022

Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Chengdu, Sichuan, China
    West China hospital of Sichuan University
Nov 1, 2021

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

Patterns and Key Healthcare Resource Use in Acute Myeloid

Completed
  • Acute Myeloid Leukemia (AML)
  • Treatment patterns among AML patients
  • AML-related healthcare resources
  • Charlotte, North Carolina
    Sermo
Jan 25, 2022

New Cytokine-based Dynamic Stratification Based on FLt3 Ligand

Recruiting
  • Acute Myeloid Leukemia
  • No intervention
  • Strasbourg, Bas-Rhin, France
  • +24 more
Aug 25, 2021

Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)

Active, not recruiting
  • Leukemia, Acute Myeloid (AML)
  • Birmingham, Alabama
  • +125 more
Aug 9, 2022

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose

Active, not recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Beijing, China
  • +47 more
Aug 17, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Feb 6, 2022

Response to Immune Checkpoint Blockade in Metastatic Melanoma

Completed
  • Melanoma
  • F-FDG PET/CT
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Jul 7, 2022

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large

Completed
  • Lymphoma
  • +2 more
  • FLT-PET/CT
  • +2 more
  • Los Angeles, California
  • +3 more
May 6, 2021